
Teva Pharmaceutical Industries Limited: updates and filings
Price
$42.62
November 17, 2026Market cap $49.0B
What Ploutos Investor adds for Teva Pharmaceutical Industries
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 3, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
September 2026
July 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 3, 2026Results of operationsForm8-K
- Nov 2, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 29, 2026Officer or director changeForm8-K
- Sep 16, 2026Material agreement entered, new material financial obligationForm8-K
- Sep 14, 2026Other material eventsForm8-K
- Sep 14, 2026Securities listed on an exchange (amendment)Form8-A12B/A
- Sep 14, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- Sep 11, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 3, 2026Other material eventsForm8-K
- Sep 3, 2026Change to shareholders' rightsForm8-K
- Jul 29, 2026FilingFormF-6 POS
- Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 29, 2026Results of operationsForm8-K
- May 28, 2026Shareholder voteForm8-K
- Apr 29, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 29, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 31, 2026Additional annual meeting materialFormDEFA14A
- Mar 31, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 31, 2026Annual meeting proxy statementFormDEF 14A
- Feb 18, 2026Filing (amendment)Form144/A
- Feb 17, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 9, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 3, 2026 | 8-K | Results of operations | Document |
| Nov 2, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 29, 2026 | 8-K | Officer or director change | Document |
| Sep 16, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Sep 14, 2026 | 8-K | Other material events | Document |
| Sep 14, 2026 | 8-A12B/A | Securities listed on an exchange (amendment) | Document |
| Sep 14, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| Sep 11, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 3, 2026 | 8-K | Other material events | Document |
| Sep 3, 2026 | 8-K | Change to shareholders' rights | Document |
| Jul 29, 2026 | F-6 POS | Filing | Document |
| Jul 29, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 29, 2026 | 8-K | Results of operations | Document |
| May 28, 2026 | 8-K | Shareholder vote | Document |
| Apr 29, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 29, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 31, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 31, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 31, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Feb 18, 2026 | 144/A | Filing (amendment) | Document |
| Feb 17, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 9, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 2, 1996. Of its note and share prospectuses (424B, FWP), the newest 40 of 63.
The full analysis
What do Teva Pharmaceutical Industries's filings show?
The filings are where every one of Teva Pharmaceutical Industries's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.